Tower Research Capital (TRC)’s BioNexus Gene Lab BGLC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15 Buy
+12
New +$19 ﹤0.01% 5835
2024
Q1
– Sell
-583
Closed -$3.09K – 5854
2023
Q4
$3.09K Buy
+583
New +$3.32K ﹤0.01% 5126

Other funds holding BGLC

Tower Research Capital (TRC)'s BGLC Position: Q3 2026 in Review

Tower Research Capital (TRC) opened a new position in BioNexus Gene Lab (BGLC) in Q3 2026: 12 shares worth $15. The stake represents ﹤0.01% of the portfolio and ranks #5835 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in BGLC as recently as Q4 2023.

Tower Research Capital (TRC) first reported a position in BGLC in Q4 2023 and has held it in 2 quarters since. The position peaked at $3.09K in Q4 2023. 4 funds tracked by Wall St. Rank hold BGLC as of Q3 2026.

  • Tower Research Capital (TRC) held 12 shares of BioNexus Gene Lab worth $15 as of Q3 2026.
  • BioNexus Gene Lab was a new Tower Research Capital (TRC) position in Q3 2026.
  • BioNexus Gene Lab made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5835 holding.
  • Tower Research Capital (TRC) first reported a position in BioNexus Gene Lab in Q4 2023 and has held it in 2 quarters since.
  • Tower Research Capital (TRC)'s BioNexus Gene Lab position peaked at $3.09K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.